NCG-X Mouse

The NCG-X is a triple-immunodeficient NCG mouse with a point mutation in c-KIT (CD117) leading to loss of endogenous Kit function. The lack of Kit expression impairs mouse hematopoietic stem cells supporting engraftment of human hematopoietic stem cells without irradiation. This NCG strain will allow for humanization without myeloablation. It also demonstrates enhanced hematopoietic chimerism in peripheral blood compared to engrafted in the NCG parent strain and has higher numbers of circulating human red blood cells.OriginThe NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by introducing a W411 point mutation in the kit gene creating the NCG-X. The strain was transferred to Charles River in 2022.